Title:Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa
VOLUME: 13 ISSUE: 6
Author(s):Alexandre R. de Mello Schier, Natalia P. de Oliveira Ribeiro, Danielle S. Coutinho, Sergio Machado, Oscar Arias-Carrion, Jose A. Crippa, Antonio W. Zuardi, Antonio E. Nardi and Adriana C. Silva
Affiliation:Institute of Psychiatry - Federal University of Rio de Janeiro. Laboratory of Panic and Respiration. Rua Visconde de Piraja, 407/702, Rio de Janeiro, RJ. CEP 22410-003, Brazil.
Keywords:Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
Abstract:Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life,
productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great
psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to
review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving
animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test
(FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant
effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors
CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
